GlassScriptPhysician profile
Melissa A Lama
NPI 1134489032
$13,467.76
in general payments reported to CMS, 2019-2025
56 companies · $2,679 in 2025
The $2,679 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,521 · 2022: $3,005 · 2023: $2,621 · 2024: $2,641 · 2025: $2,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,857 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,856.55 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,433.66 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,022.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,388.35 | 2021-2025 | |
| Lilly USA, LLC | $832.15 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $800.61 | 2021-2025 | |
| Amgen INC. | $705.24 | 2021-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $561.81 | 2021-2025 | Xifaxan, Cycloset, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.84 | 2021-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Novo Nordisk INC | $420.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $406.55 | 2021-2025 | |
| Astellas Pharma US INC | $348.30 | 2021-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $240.65 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $179.78 | 2021-2025 | Trintellix |
| Esperion Therapeutics, INC. | $176.66 | 2021-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $162.11 | 2022-2024 | Verquvo, Dificid, Belsomra |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Lama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.